Conference-Abstracts-5-2016

Conference Abstracts

Below is the list of abstracts of research that was conducted as part of the Collaboration for AIDS Vaccine Discovery and presented at international conferences. Please click on the title to see more information about the abstract.

Title	Meeting	First Author	Collaborating Consortia
Circulating CCR7highCXCR5highCCR6high CD4 T cells induce in vitro isotype switching	Keystone 2013	Boswell, Kristin L.
Multiparametric Flow Analysis of HIV-specific CD8 T-cell Mediated Virus Inhibition	Keystone, HIV vaccines and Viral Immunity, March 21-26th 2010 Banff, Canada	Kopycinski, Jakub
Generation and Characterization of Recombinant CDV Expressing SIV Env Immunogens	American Society for Virology annual meeting, 2011, University of Minnesota	Zhang, Jason
Development of Recombinant Canine Distemper Virus (rCDV) Vectors for SIV/HIV Vaccine Delivery	Negative Strand Virus Meeting, Spain	Zhang, Xinsheng
Automated HIV pseudovirus production for vaccine trials and a new model for estimation of cell proliferation dynamics using CFSE data	28thFebruary 2013; Invitation by Colonel William Geesey, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand	A. Meyerhans
Automated HIV pseudovirus production for vaccine trials and a new model for estimation of cell proliferation dynamics using CFSE data	Invitation by Prof. Dr. Ruengpung Sutthent, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.	A. Meyerhans
Comparative Evaluation of Assays for Fc Receptor-Mediated Antibody Effector Functions Targeting HIV-1	AIDS Vaccine, Barcelona, Spain	Ackerman, M.E.	Ackerman/Alter: Leveraging Antibody Effector Function;#Lewis: Ab Specificity & Fc-Mediated Protection;#Walker: HIV Control & Immunogen Design;#*Other;#Self: VISC
Comparative Evaluation of Assays for Fc Receptor-Mediated Antibody Effector Functions Targeting HIV-1	AIDS Vaccine, Barcelona, Spain	Ackerman, M.E.	Montefiori: Ab VIMC;#Gottardo: VISC
Increased Tim-3 expression on T cells in chronic HIV-1 infection	AIDS Vaccine 2008, Cape Town	Addo, M
Structural Model of gp120 Surface of Infection Based on Positional Charge Differences between X4- and R5-tropic viruses	AIDS Vaccine 2007 - Seattle	Agarwal, A
Quantitative Assessment of HIV-1 Neutralization Epitope Masking	AIDS Vaccine 2010, Atlanta	Agarwal, Alpna
Phospholipid binding and neutralization by anti-gp41HIV-1 Envelope antibodies	AIDS Vaccine 2007 - Seattle	Alam, S	Montefiori: Ab VIMC;#Zolla-Pazner: Epitope-Scaffold Immunogens
Induction of antibodies with specificity for gp41 neutralizing epitopes by membrane anchored gp41 immunogens	AIDS Vaccine 2010, Atlanta	Alam, S. Munir
Reverted unmutated ancestor 2F5 VH2-5 alleles differentially bind gp41 and bacterial antigens: a potential genetic basis for gp41 neutralizing B cell responses	AIDS Vaccine 2010, Atlanta	Alam, S. Munir.
The role of lipid reactivity of HIV-1 gp41 membrane proximal antibodies in neutralization of HIV-1: Novel liposome based immunogen design	AIDS Vaccine 2008, Cape Town	Alam, SM
HIV-1 Env gp41 Abs that mask neutralizing epitopes - production in HIV-1 infection and potential for reg of gp41 MPER NAbs	AIDS Vaccine 2007 - Seattle	Alam, SM	Haynes: Broad Neutralizing Antibody Consortium;#Montefiori: Ab VIMC
Redesign of Replicating LucR HIV-1 Reporter Viruses with Innovative IRES Elements for Expanded Immune Monitoring Applications	AIDS Vaccine, Barcelona, Spain	Alberti, M.O.	*Other
Novel IRES elements in replicating LucR reporter HIV-1 for expanded immune monitoring approaches	Keystone Symposia, Banff Alberta Canada	Alberti, M.O.
Ultra-Deep Sequencing of Full-Length HIV-1 Genomes Identifies Rapid Viral Evolution During Acute Infection	AIDS Vaccine 2009, Paris	Allen, T
CD8+ T cell public clonotype usage in a single epitope-specific response in acute SIV infection of Mamu-B*08 positive rhesus macaques may determine control of viral replication	Keystone, Whistler, March 2011	Almeida JR
Dynamic Characterization of the V3 Loop Crown	AIDS Vaccine 2007 - Seattle	Almond, D
Sequence variability in the crown of the V3 loop of the HIV-1 envelope is clustered within a small 3D structural zone	AIDS Vaccine 2009, Paris	Almond, D
Map of broad and narrow neutralization in the V3 loop crown	AIDS Vaccine 2010, Atlanta	Almond, David
Pre-clinical Evaluation of Novel T cell vaccines in MHC Characterised Cynomolgus Macaques	HIV Vaccines, 2012, Keystone, CO	Almond, Neil
ADCC Titers to HIV-Infected Cells are Detectable in the Majority of Vaccine Recipients in the RV144 Trial	AIDS Vaccine, 2011, Bangkok Thailand	Alpert, M.D.	*Other;#Self: VISC
Immune recognition of HIV-1 during acute infection	AIDS Vaccine 2009, Paris	Altfeld, M
Characterizing the innate immune response in HVTN 071, a trial using MRKAd5 gag/pol/nef from the STEP study	AIDS Vaccine 2008, Cape Town	Andersen-Nissen, E
A comparison of systemic innate immune responses to the MRKAd5/HIV and MVA/HIV candidate HIV vaccines	AIDS Vaccine 2010, Atlanta	Andersen-Nissen, Erica
A comparison of systemic innate immune responses to the MRKAd5/HIV and MVA/HIV candidate HIV vaccines	Keystone Symposia - Immunological Mechanisms of Vaccination, 2010, Seattle	Andersen-Nissen, Erica
Vaccination with MVA/HIV Induces Differential Recruitment of Monocyte Subsets Into The Circulation And Monocyte-Specific Transcriptional Programs	AIDS Vaccine 2012, Boston	Andersen-Nissen, Erica
The Genetic Complexity of HIV-1 env in Subtype B and C Transmission Pairs	HIV Acute Infection Meeting – Boston, MA - 2009	Anderson, J
Regulatory T cell frequencies correlate with T cell activation in chronic HIV-1 infection (poster)	AIDS Vaccine 2009, Paris	Angin, M
Biophysical Dissection of the Antigen-Antibody Interaction of the Broadly Reactive Anti-V3 Human mAb 447-52D	AIDS Vaccine 2012, Boston, MA	April Killikelly
HIV-1 Subtype C Diversity in an Adult Cohort of Progressors and Non-progressors Using Single Genome Amplification	CROI 2009 - Montreal	Arcary, Derseree
Assessment of Ad vectors expressing full or fragmented HIV genetic components	International Union of Biochemistry and Molecular Biology 2009	Athanasopoulos Takis	Self: VISC
Development and assessment of thermo-stable Adenovirus (Ad)-based vaccines expressing ubiquitinated and genetically fragmented HIV/SIV genetic components	British Society for Gene Therapy, 2010, Royal Holloway University of London	Athanasopoulos Takis	Self: VISC
Ubiquitination and segmentation of HIV genetic components: Aiming towards an HIV vaccine inducing broad(er) T cell immune responses	European Society for Gene and Cell Therapy 2008 - Brugge	Athanasopoulos, T
Assessment of adenoviral vectors expressing HIV genetic components: Aiming towards a thermo-stable HIV vaccine inducing broad T cell immune responses	British Society for Gene Therapy 2009 - London	Athanasopoulos, T
A vaccination strategy harnessing the adjuvanticity of skin dendritic cells with modified adenoviral vectors	Society for General Microbiology 2009 - Harrogate	Bachy, V
Development of a 'Stealth' Adenovirus Vaccine Vector	British Society for Gene Therapy 2008 - Edinburgh	Bachy, V
Harnessing skin dendritic cells as a vaccination strategy	Europrise 2008 - Malta	Bachy, V
New neutralizing monoclonal antibodies from HIV-1 subtype C and CRF02_AG infected people	Ehrlich 2008 - Germany	Balla-Jhagjhoorsingh, S
The importance of well-defined HIV-1 neutralization assays	AIDS Vaccine 2009, Paris	Balla-Jhagjhoorsingh, S
HJ16 induced resistant virus displays rare natural mutation highlighting the conserved nature of this new CD4bs epitope	AIDS Vaccine 2010, Atlanta	Balla-Jhagjhoorsingh, Sunita
4e10 epitope-scaffolds mimic the antibody-bound epitope conformation	AIDS Vaccine 2009, Paris	Ban, YA
Genetic characterization and determination of multiplicity of infection using single genome amplification of recently transmitted HIV-1 env variants from a cohort with multiple circulating HIV-1 subtypes in Mbeya, Tanzania	IAS 2009 - Cape Town	Bandawe, G
Multiplicity of infection by HIV-1 in injection drug users, men who have sex with men and heterosexuals.	AIDS Vaccine 2009, Paris	Bar KB
Neutralizing Antibody Responses Against Conformational Envelope Epitopes in Early HIV-1 Infection	AIDS Vaccine 2009, Paris	Bar KJ
Novel Adenovirus Vector-Based Vaccines for HIV-1	AIDS Vaccine 2008, Cape Town	Barouch, D
HIV-1 Mosaic Antigens Expand Cellular Immune Breadth and Depth in Rhesus Monkeys	AIDS Vaccine 2009, Paris	Barouch, Dan
First-in-Human Phase 1 Safety and Immunogenicity of an Adenovirus Serotype 26 HIV-1 Vaccine Vector	AIDS Vaccine 2009, Paris	Barouch, Dan
Alternative Serotype Adenovirus Vectors	AIDS Vaccine 2010, Atlanta	Barouch, Dan
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Results of the randomized multicentre EV03/ANRS Vac20 Phase I/II Trial	CROI 2010, San Francisco	Bart, Pierre-Alexandre
LabKey Software: An Open-Source Repository and Portal for Lab and Clinical Data	BioIT Conference 2008 - Vancouver	Bellew, M
An HIV-1-based screening platform for selection of envelopes with high affinity for broadly neutralizing antibodies	AIDS Vaccine 2009, Paris	Benen, T
Adenovirus Vectors Induce Expansion of Memory CD4 T Cells with a Mucosal Homing Phenotype that are Readily Susceptible to HIV-1 Infection	AIDS Vaccine 2008, Cape Town	Benlahrech, A
Adenovirus vectors induce expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 infection	AIDS Vaccine 2009, Paris	Benlahrech, A
Fragmentation of SIV-gag Induces Broader T cell Responses In Vitro	AIDS Vaccine 2011, Bangkok, Thailand	Benlahrech, Adel
Using a Quality Management Software at Duke University Medical Center	Society of Quality Assurance Annual Meeting, Nevada, USA	Bernstein, E.
Improvements to the Auditing System by the Quality Assurance for Duke Vaccine Immunogenicity Programs: Lessons Learned	SQA Annual Meeting, Grapevine, TX	Bernstein, E.	*Other
Suppression of human dendritic cell function during acute HIV infection	AIDS Vaccine 2009, Paris	Bhardwaj , N
Broader Selection of Rare CTL Escape Mutations in Elite Controllers Supports a Role of Viral Replication Defects in the Control of HIV-1	Keystone, 2011, Whistler, British Columbia, Canada	Bhoumik, Priyasma
Profiling the Specificity of Neutralizing Activity in a Panel of HIV+ Plasmas from Subtypes B and C Chronic Infections	AIDS Vaccine 2008, Cape Town	Binley, J
Role of Complex Carbohydrates in Human Immunodeficiency Virus Type 1 Infection and Resistance to Antibody Neutralization	AIDS Vaccine 2010, Atlanta	Binley, J.M.
Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors	AIDS Vaccine 2009, Paris	Binley, JM
Engineering Immunity against HIV-1	CROI 2010, San Francisco	Bjorkman, Pamela
The Problems with Persistent Viral Infections	Workshop on the Immunological Basis of Vaccine Efficacy 2009 - Seattle	Blattman, J
Use of Retinoic Acid as an Adjuvant during Vaccination Results in Increased Central Memory T cells and also Imprints Gut Mucosal Homing Properties to Memory T Cells	AIDS Vaccine 2009, Paris	Blattman, J	McElrath: Innate to Adaptive Immunity
Developing a Quantitative Model of Antibody Effector Function.	AIDS Vaccine, Boston MA	Boesch, Austin
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimicking Antibody	Keystone HIV Vaccines	Bonsignori M
ADCC-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Preferentially Use the VH1 Gene Family	AIDS Vaccine, Boston, MA	Bonsignori, Mattia
Recombination of HIV-1 gp160 clones with viral backbone DNA through co-transfection to produce pseudoviruses can create replication competent viruses	AIDS Vaccine 2008, Cape Town	Borges, AR
Developing assays to characterise and phenotype long lived memory T cells	AIDS Vaccine 2008, Cape Town	Bourne, V
Escape Mutations in Gag Associated with Protective HLA Alleles Substantially Impact Viral Replication Capacity	HIV Acute Infection Meeting, Boston, MA - 2009	Boutwell, C
Ultra-Deep Whole Genome HIV Sequencing Reveals the Impact of Viral Adaptiation on Immune Control During Acute Infection	Keystone, 2011, Whistler, British Columbia, Canada	Boutwell, Christian L
CTL Escape Mutations in Gag Epitopes Restricted by Protective HLA Class I Alleles Cause Substantial Reductions in Viral Replication Capacity	AIDS Vaccine 2009, Paris	Boutwell, CL
Hexon hypervariable regions 4-7 contain important Ad5-specific neutralizing antibody epitopes	AIDS Vaccine 2009, Paris	Bradley, RR
Crystal structure analysis of anti-V2 Mab 2158 suggests a conformation epitope involving an N-linked glycosylation site	AIDS Vaccine 2012, Boston, MA	Brett Spurrier
Generation of multiple HIV-1 subtype C envelope single-genome amplification (SGA) products from recent infection cervico-vaginal lavage samples	AIDS Vaccine 2008, Cape Town	Bronwen, E
Influence of NK Cells and NK Cell Receptor Polymorphisms in the Assessment of HIV-1 Neutralization	AIDS Vaccine, 2011, Bangkok Thailand	Brown, B.K.
Characterization of the influence of PBMC donor parameters on HIV-1 PBMC neutralization assay variability: implications for assay standardization	AIDS Vaccine 2008, Cape Town	Brown, BK
Characterization of leukopak PBMC phenotypes and biotypes for optimal performance in HIV-1 neutralization assays	AIDS Vaccine 2009, Paris	Brown, BK
Systematic profiling of polyclonal HIV antibodies and prediction of effector functions	AIDS Vaccine, Barcelona, Spain	Brown, E.P.
Systematic Profiling of Polyclonal HIV Antibodies and Prediction of Effector Functions	AIDS Vaccine, Boston MA	Brown, Eric
Reversion of HLA-associated polymorphisms in Gag, Pol and Nef during the first year of HIV infection: Sites, rates and pVL correlations	AIDS Vaccine 2008, Cape Town	Brumme, CJ
Combined clinical and immunological biomarkers predict rates of CD4 decline in chronic untreated HIV infection	AIDS Vaccine 2008, Cape Town	Brumme, Z
Relationship between HLA class I-driven evolution in Gag, Pol and Nef and clinical markers of HIV disease: a multi-center collaborative study	AIDS Vaccine 2008, Cape Town	Brumme, ZL
Cell-surface Display and Panning of HIV-1 derived Envelope proteins	AIDS Vaccine 2009, Paris	Bruun, TH
Evolution of HIV-1 subtype B viruses and neutralization patterns with heterologous anti-HIV-1 antibodies	AIDS Vaccine 2008, Cape Town	Burda, S
Structural Characterization of Neutralizing Human Anti-V3 Monoclonal Antibodies 3074 and 268-D	AIDS Vaccine 2008, Cape Town	Burke, V
A glycan-V1V2 HIV neutralizing antibody with a short CDRH3 showing a mode of recognition distinct from other V1V2-speci c antibodies	Keystone HIV Vaccines	Cale EM
Transcriptional profiling of RV144 participants reveals a gene expression signature that correlates with immunogenicity.	AIDS Vaccine 2013, Barcelona, Spain.	Cameron, Mark
Structural Basis for Coreceptor Selectivity by the HIV Type 1 V3 Loop	AIDS Vaccine 2007 - Seattle	Cardozo, T
Worldwide epitope prevalence of crystallographically resolved anti-V3 antibodies	AIDS Vaccine 2009, Paris	Cardozo, T
Engineered Immunogen Presenting an Epitope Recognized by a Neutralizing mAb Elicits Antibodies that Recapitulate the mAb’s Specificity	AIDS Vaccine 2010, Atlanta	Cardozo, Timothy
A Computationally Designed Immunogen Elicits Potent Anti-V3 Neutralizing Antibodies	AIDS Vaccine 2009, Paris	Carrico, C	Montefiori: Ab VIMC
Immunogenetic variation charaterizing exceptional control of HIV	Keystone 2009	Carrington M
Immunogenetic effects on HIV-1 infection	Keystone Symposia on Human Immunology and Immunodeficiences 2009 - Beijing	Carrington M
TLR-mediated pDC responses to HIV-1 ligands	AIDS Vaccine 2009, Paris	Chang, JJ
HIV-1 elite controllers resist HIV-1 infection via p21 (cip-1/waf-1)	AIDS Vaccine 2010, Atlanta	Chen, H
Inter-Lab Calibration of Biomarker Data with Censoring	Joint Statistical Meeting, Boston, MA	Chen, S
Human domain antibodies targeting conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers	AIDS Vaccine 2008, Cape Town	Chen, W
Monoclonal antibodies from patient with acute HIV-1 infection	AIDS Vaccine 2009, Paris	Chen, W
Limited introductions and genetic variation of HIV-1 in a MSM cohort in China.	AIDS Vaccine 2010, Atlanta	Chen, Y.
Biochemical, Immunological and Structural Characterization of a Panel of Novel Rabbit Monoclonal Antibodies Elicited by HIV-1 Env VaccinationA V2 Conformational Immunodominant Epitope Recognized by Human Monoclonal Antibodies	AIDS Vaccine, Barcelona Spain	Chen, Y.	Montefiori: Ab VIMC
The effect of Ad5 capsid- and fiber- specific neutralizing antibodies on vaccine-induced immunity and outcome in the STEP trial	AIDS Vaccine 2010, Atlanta	Cheng, C
Generating Viruses Matching RV144 Vaccine Components to Explore Efficacy.	AIDS Vaccine, 2011, Bangkok Thailand	Chenine, A.
Neutralization assay using a CD4+ T cell line and chimeric CRF01_AE IMC_LucR.T2A	AIDS Vaccine 2010, Atlanta	Chenine, Agnes-Laurence
Full-length IMC expressing Renilla Luciferase for neutralization assay using PBMC	AIDS Vaccine 2009, Paris	Chenine, A-L
Skewed HIV-1-specific CD4+ Th2 helper cell contribution in progressive HIV-1 infection	AIDS Vaccine 2009, Paris	Chevalier, M
Increased control of viral replication by HIV-1-specific CD8+ T cells mediated by HIV-specific CD4+ T helper signals	HIV Vaccine Keystone, Banff, Canada - 2009	Chevalier, M
Skin Tattooing as an Effective Tool for Delivering DNA and Protein Vaccine Immunogens	AIDS Vaccine, 2012, Boston	Chiu, Yung-Nung
A phase I/II trial of preventive HIV vaccination with DNA and poxviral-vector in healthy subjects EV03/ANRS VAC20: Cytokine production by T cells.	AIDS Vaccine	Christine Lacabaratz
Distinct HIV-specific antibody Fc-profiles in RV144 and VAX003	AIDS Vaccine Conference	Chung, Amy,
Vector induced skewing of antibody Fc-effector functions	AIDS Vaccine, Boston MA	Chung, AW
RV144 Vaccination induces a different antibody effector function profile in comparison to VAX003	Keystone Symposia- HIV Vaccines	Chung, AW
Improving Cell Surface Expression and Immunogenicity of HIV-1 Envelope	CAVD Annual Meeting 2012, Seattle, WA	Conde, Angela
Improving Cell Surface Expression and Immunogenicity of HIV-1 Envelope	AIDS Vaccine 2013, Barcelona, Spain	Conde, Angela
Structural characterization of HIV Env neutralization sensitivity	Keystone HIV Vaccines	Cottrell CA
Relationship of HIV-1 and SIV Envelope Glycoprotein Trimer Occupation and Neutralization	AIDS Vaccine 2008, Cape Town	Crooks, ET
The role of conformational dynamics in modulating HIV gp120 antigenicity	Keystone Symposium Vaccines (X2), Keystone, CO	Davenport, Thaddeus M.
Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX B/E® in RV144 Vaccine Recipients	Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery 9th Anniversary Meeting 2014	David Easterhoff	Montefiori: Ab VIMC
Induction of antibodies with long variable heavy third complementarity determining regions and glycan binding by repetitive boosting with a HIV vaccine	2015 Keystone	David Easterhoff	Montefiori: Ab VIMC
Assay conditions with primary HIV-1 isolates giving neutralization rates proportional to Ab concentration and in vivo protection	AIDS Vaccine 2007 - Seattle	David, D
HIV-2/HIV-1 Envelope Chimeras Detect High Titer Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma	CROI 2009 - Montreal	Davis, KL
Genome-wide Association Analysis	CROI 2009 - Montreal	de Bakker, P
A Genome-wide Association Study in HIV-1 Controllers	CROI 2009 - Montreal	de Bakker, P
Comparative Analysis of SIV-Gag specific T Cell Immunity Following Immunization with Human- and Simian-Derived Adenoviral Vectors	Keystone Symposia - Immunological Mechanisms of Vaccination, 2010, Seattle	De Costa, Andreia
B cells do not play a major role in SIVmac239 nef-mediated protection against SIVmac239 challenge	AIDS Vaccine 2008, Cape Town	De La Rosa, M	Letvin: rAdenoviral & rMycobacterial Vector Immunogens
B cells play a marginal role in SIV mac 239 nef-mediated protection against SIV mac 230 challenge	CROI 2009 - Montreal	De La Rosa, M
Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes	Keystone HIV Vaccines	de Taeye SW
Inducing HIV-1 neutralizing antibodies with native-like envelope trimers	Keystone HIV Vaccines	De Taeye SW
High-Resolution Cryoelectron Microscopy studies of the HIV- 1 Env protein in complex with bnAbs	Keystone HIV Vaccines	de Val N
A Genome-wide Association Study in HIV-1 Controllers	NIH/OAR Genomic Analyses of HIV Infection 2009 - Bethesda	deBakker, Paul
Whole Genome Association Studies: Understanding the Genetic Basis of Susceptibility to Infectious Diseases	ASTMH 2008 - New Orleans	deBakker, Paul
Role of Toll-like receptor (TLR), RIG-I-like receptor (RLR) and Nod-like receptor (NLR) pathways in innate immune responses elicited by poxvirus	Toll 2008 - Lisbon	Delaloye, J
Glycopeptide analysis of individual glycosylation sites of HIV envelope oligomers that induce breadth in neutralizing antibodies	AIDS Vaccine 2007 - Seattle	Desaire, H
Glycosylation: An important factor in Env diversity	AIDS Vaccine 2009, Paris	Desaire, H
All Known Cross-reactive HIV-1 Neutralizing Antibodies Are Highly Divergent from Germline and their Elicitation May Require Prolonged Periods of Time	AIDS Vaccine 2008, Cape Town	Dimitrov, DS
Crystal structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody	WCPCW, 2011, California	Diskin, Ron
Crystal structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody	The 25th Annual Meeting of the Groups Studying the Structures of AIDS-Related Systems and Their Application to Targeted Drug Design, 2011, Maryland	Diskin, Ron
Fresh Cohort; Acute HIV-1 Infection In Cohort Of High Risk Hiv Negative Women In KZN, South Africa	Conference on Retroviruses and Opportunistic Infections (CROI), Boston, MA, USA	Dong, Krista
A unique inflammatory signature that tracks with the development of bNAbs in the absence of high viremia	Keystone, Banff, Canada	Dugast, Anne-Sophie	Ackerman/Alter: Leveraging Antibody Effector Function;#Montefiori: Ab VIMC
An inflammatory profile that predicts the development of neutralizing antibody breadth	HIV R4P, Cape Town, South Africa	Dugast, Anne-Sophie	Montefiori: Ab VIMC
Dramatic changes in Fc-receptor expression during HIV-1 infection associated with reduced phagocytic activity during progressive HIV-1 infection (Poster)	AIDS Vaccine 2009, Paris	Dugast, AS
ChameleonLab®: A laboratory knowledge and workflow management system based on low temperature electronics	WOLTE 2008 - Ilmenau, Germany	Durst, C
Dimension reduction for identification of candidate immune correlates of vaccine efficacy	Joint Statistical Meeting, Chicago, IL	Edlefsen, P
Development of a "Stealth" Adenovirus vaccine vector	Keystone Meeting 2008 - Banff	El-Doueik, H
Breadth and Magnitude of Neutralizing Antibody Responses in Subjects Infected with HIV-1 Subtype D or D Containing Recombinants in Rakai District, Uganda	AIDS Vaccine 2009, Paris	Eller, LA
Thermostability of well-ordered HIV spikes correlates with the elicitation of tier 2 neutralizing antibodies	Keystone HIV Vaccines	Feng Y
Establishing PBMC Repository for T Cell Assays Optimization and Proficiency Testing in Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) Laboratories.	AIDS Vaccine 2008, Cape Town	Ferrari, G
Mapping of ADCC Activity: The A32 Conformational C1 Epitope is a Dominant Target for ADCC Antibodies in Chronically HIV-1 Infected Subjects	AIDS Vaccine, 2011, Bangkok Thailand	Ferrari, G.	*Other
Development of a Long-Term Peripheral Blood Mononuclear Cells (PBMC) Repository (2007-2011) at Duke University Medical Center (DUMC) that Maintains Interferon-γ Functionality for ELISpot and Flow Cytometry	AIDS Vaccine 2011, Bangkok	Ferrari, Guido
Development and statistical modeling of an intracellular cytokine staining baseline-adjusted vaccine-specific response criteria for tuberculosis.	31st Congress of the International Society for Advancement of Cytometry, Seattle, WA	Finak G
ggcyto: A New Flow Cytometry Data Visualization Framework for Bioconductor Based on ggplot	31st Congress of the International Society for Advancement of Cytometry, Seattle, WA	Finak G
Modulation of the RAS pathways as a means to improve the efficacy of vaccine candidates for HIV	The Palm Springs Symposium on HIV/AIDS, Palm Springs	Franchini, Genoveffa
Adjuvants Influence the Magnitude, Quality and Durability of HIV Env Specific Humoral Immunity in Non-human Primates	AIDS Vaccine 2012	Francica, J.R.	Montefiori: Ab VIMC
Evaluation of the Yellow Fever Virus Vaccine Strain 17D as a New Vector for HIV-1 Vaccine Development	AIDS Vaccine 2008 - Cape Town	Franco, D
Immunogenicity Studies of Chimeric Yellow Fever 17D Viruses Carrying HIV-1 p24 Antigen	AIDS Vaccine 2009 - Paris	Franco, D
GHRC/CAVD-technology: new identification, storage and distribution technologies for vaccine related reagents and specimens	AIDS Vaccine 2010, Atlanta	Frank R. Ihmig
"GHRC/CAVD-technology: new identification, storage and distribution technologies for vaccine related reagents and specimens"	AIDS Vaccine 2010, Atlanta Georgia, 28 Sep - 1 Oct	Frank R. Ihmig
A Simple Approach to Secure and Test Data Analysis Tools in GCLP-compliant Academic Laboratories	SQA Annual Meeting, Grapevine, TX	Frazier, J.	*Other
Development of a 32-bit microcontroller-based cryotank backplane system for use in the "Global HIV Vaccine Research Cryorepository"	WOLTE 2008 - Ilmenau, Germany	Fuchs, CC
Thwarting HIV evasion of antibody avidity with novel antibody architectures	Immunochemistry & Immunobiology (Gordon Conference), Newry, ME	Galimidi, Rachel
Molecular insights into the evolution of a potent family of HIV antibodies	Keystone HIV Vaccines	Garces F
Endotoxin-mediated Inhibition of HIV-1 in Peripheral Blood Mononuclear Cells but Not in TZM-bl Cells: A Cautionary Note for Neutralizing Antibody Assays	CROI 2009 - Montreal	Geonnotti, A	Montefiori: Ab VIMC
Endotoxin-mediated Inhibition of Human Immunodeficiency Virus Type 1 in Peripheral Blood Mononuclear Cells but Not in TZM-bl Cells: A Cautionary Note for Neutralizing Antibody Assays	CROI 2009 - Montreal	Geonnotti, A
Computationally identified mutations suspected to cause gp120 charge inversion and gp41-mediated allosteric effects impact IgG1b12 susceptibility	AIDS Vaccine 2010, Atlanta	Geonnotti, A. R.
Global HIV Vaccine Research Cryorepository – GHRC	2nd Global Vaccine Congress 2008 - Boston	Germann, A
Global HIV Vaccine Research Cryorepository – GHRC	German Society for Virology 2009 - Leipzig	Germann, A
Centre for AIDS Reagents – Provision of Reagents for AIDS Vaccine and Microbicide Research	EUROPRISE Annual Conference 15-18 November 2010, Tiara Park Atlantic Lisbon, Portugal	Gilbert, Sarah
Excellent concordance between IFN-gamma ELISpot results in two Comprehensive T Cell Vaccine Immune Monitoring Consortium (CTC-VIMC) Laboratories.	AIDS Vaccine 2008, Cape Town	Gilmour, J
Genetic signature analysis identifies the CD4i region of gp120 as a determinant of broadly NAb responses in HIV-1-infected individuals	AIDS Vaccine 2009, Paris	Gnanakaran, S
Priming with Adenovirus26 Vaccines Affects ALVAC-SIV/gp120 Vaccine Efficacy tested in a SIVmac251 Challenge Model Performed One-month Post-Vaccination	AIDS Vaccine 2013, Barcelona, Spain	Gordon, Shari N
Altering the Prime Affects ALVAC-SIV/gp120 Immunogenicity and Efficacy	CROI, Boston, MA	Gordon, Shari N
Human Anti-V2 Monoclonal Antibodies Neutralize Tier 1 HIV-1 Pseudoviruses	AIDS Vaccine - Bangkok, Thailand	Gorny, M.K.	Montefiori: Ab VIMC
CD4 binding site, V3 and V2 human monoclonal antibodies with a low rate of mutations display comparable neutralizing activity against HIV-1 pseudoviruses.	HIV Vaccines, 2012, Keystone, CO.	Gorny, Miroslaw K.	Montefiori: Ab VIMC
A human anti-V3 monoclonal antibody encoded by the rarely used VH1-69 gene recognizes an unusual V3 structure	B Cell Development and Function, Keystone, CO	Gorny, Miroslaw K.
Cross-neutralizing activity of human anti-HIV-1 monoclonal antibodies do not correlate with the percentage of mutations in their variable fragments	Human Antibodies & Hybridomas, Orlando, FL	Gorny, Miroslaw K.	Montefiori: Ab VIMC
Germline variable genes code for contact residues maintained during affinity maturation of human anti-V3 monoclonal antibodies encoded by VH5-51	AIDS Vaccine 2010, Atlanta	Gorny, Miroslaw, K
Immunoglobulin Gene Usage by Neutralizing Human Anti-V3 HIV-1 Monoclonal Antibodies Derived from Clade B and Non-B HIV-1-infected Individuals	AIDS Vaccine 2008, Cape Town	Gorny, MK
Human anti-V3 monoclonal antibodies (mAbs) from non-clade B-infected individuals display cross-clade neutralization	AIDS Vaccine 2007 - Seattle	Gorny, MK
Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies	AIDS Vaccine 2009, Paris	Gorny, MK	Self: VISC;#Montefiori: Ab VIMC
Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization	Keystone 2010, Banff Canada	Gray, E
Creating a mouse model for human immune responses: Transferring human genes rather than human cells	Grand Challenge Meeting - 2009	Greenberg, P
Expression Of Broadly Neutralizing Antibodies (NAbs) Against HIV In RAG KO Mice	ASGCT, 2012, Philadelphia, PA	Greig, Jenny A
AAV2/8 transduces skeletal muscle in non-human primates at efficiencies equal to or greater than that observed in mice	ASGCT, 2012, Philadelphia, PA	Greig, Jenny A.
Impact Of Pre-Existing Neutralizing Antibodies (NAbs) On Expression Of A SIV Antibody Following Intramuscular (IM) Administration Of AAV2/8	ASGCT, 2012, Philadelphia, PA	Greig, Jenny, A
A Common Transitional Structure Revealed by a New Broadly Neutralizing Antibody as a Novel HIV-1 Vaccine Candidate	AIDS Vaccine 2013, Barcelona, Spain	Guan, Y.	Montefiori: Ab VIMC;#Gallo: Systemic, Mucosal & Passive Immunity
Diversity of Antibody Germline Gene and HIV-1 Infection: Implication for HIV-1 Vaccine	14th Annual International Meeting of the Institute of Human Virology	Guan, Yongjun	Gallo: Systemic, Mucosal & Passive Immunity
Display of the HIV-1 Env MPER in the context of a well- ordered soluble uncleaved (NFL) trimer	Keystone HIV Vaccines	Guenaga J
All-atom ensemble modeling with small angle X-ray scattering data as a tool for the structural characterization of glycoproteins	Keystone Structural Analysis of Supramolecular Assemblies by Hybrid Methods (C1)	Guttman, Miklos
Primary HIV-1 isolates in infected drug naïve individuals that evolve increase neutralization sensitivity to anti-gp120 monoclonal antibodies (mAbs).	AIDS Vaccine 2010, Atlanta	Haldar, Bijayesh
Particulate Delivery of Small-Molecule Immunomodulators to Enhance a Liposomal HIV Epitope Vaccine	Biomedical Engineering Society 2013 Annual Meeting, 9/26/2013	Hanson, Melissa
Shaping humoral responses against HIV env antigens via lipid nanoparticle vaccine delivery	2012 Keystone Symposia meeting on HIV Vaccines	Hanson, Melissa
Cytotoxic activity of virus-specific CD8 T-cells correlates with perforin and GrmB expression and differentiation stage but not with GrmA or GrmK	CROI 2009 - Montreal	Harari, A
Cytotoxic Activity of Virus-Specific CD8 T-Cells Correlates with Perforin and GrzB Expression and Differentiation Stage but not with GrzA, GrzK	AIDS Vaccine 2008, Cape Town	Harari, A
Assessment of Adenoviral Vectors in Gel Formulations for the Manufacture of Micro-Needle Skin Patches	European Society of Gene and Cell Therapy 2007 - Rotterdam	Harris, JD
A novel high throughput quantitative platform to detect HIV-1 and SIV-specific Antibody Dependent Cellular Cytotoxicity (ADCC)-mediating antibody responses.	4th Annual Measurement of Antigen Specific Immune Reponses (MASIR) Conference -2010	Hart, Lydia
Vaccine-induced Targeting of Epitopes Associated with Spontaneous Control of HIV Viral Replication is Associated with Lower Set-point Viral Loads in HIV-Infected Participants from the STEP Trial	CROI 2009 - Montreal	Heckerman, David
Rapid Appearance of Vaccine-Induced Potentially Protective anti-Env Antibody Responses with Early Co-Administration of Bivalent gp120 in Combination with NYVAC or DNA	AIDS Vaccine	Heeney Jonathan	Montefiori: Ab VIMC;#Self: VISC;#Koup: T Cell VIMC
Ultra-deep Viral Sequencing Reveals Rapid CTL Escape and Reversion Events During Acute HIV-1 Infection	Keystone 2009	Henn, M
Ultra-Deep Sequencing During Acute HIV Infection Reveals Complex Adaptive Changes to Host Selection Pressures	AIDS Vaccine, 2010, Atlanta, GA	Henn, Matthew
Sensitive Population Profiling and Genome Assembly of HIV and Flaviviruses Using Ultra-Deep Sequencing Technologies Reveals Rapid and Complex Adaptation to Host Selective Pressures	Advances in Genome Biology and Technology, 2011, Maro Island, FL	Henn, Matthew R.
Sensitive Population Profiling and Genome Assembly of HIV and Flaviviruses using ultra-deep sequencing technologies	Beyond the Genome, 2010, Boston, MA	Henn, Matthew R.
Expanding Frontiers in Viral Genomics through the application of ultra-deep sequencing technologies	NGX: Next-Generation Sequencing, 2010, Providence, RI	Henn, Matthew R.
Ultra-Deep Sequencing of Full-Length HIV-1 Genomes Identifies Rapid Viral Evolution During Acute Infection	HIV Acute Infection Meeting 2009 - Boston	Henn, MR
Sensitive Population Profiling and Genome Assembly of HIV Using Ultra-deep Sequencing Technologies	CROI 2010, San Francisco	Henn, MR
Ultra-Deep Sequencing of Full-Length HIV-1 Genomes Identifies Rapid Viral Evolution During Acute Infection	HIV Acute Infection Meeting, Boston, MA - 2010	Henn, MR
Ultra-Deep Sequencing Identifies Regions of HIV Undergoing Rapid Selection During Acute HIV Infection	AIDS Vaccine 2009, Paris	Henn, MR
Ultra-Deep Sequencing During Acute HIV Infection Reveals the Earliest Adaptive Changes to Host Selection Pressures.	17th International HIV Dynamics & Evolution Conference, Monterery, California, April 2010	Henn, MR
Ubiquitination of HIV gag protein results in increased expression of inhibitory markers	AIDS Vaccine 2011, Bangkok, Thailand	Herath, Shanthi, I.
Optimization of the Expansion of Antigen-Specific CD8+ T-cells for Use in a Viral Suppression Assay	AIDS Vaccine 2009, Paris	Herman, M
Immunogenicity and Neutralization Properties of a Trimeric MPER Containing gp41 Antigen	AIDS Vaccine 2008, Cape Town	Hinz, A
Bispecific Antibodies That Neutralize HIV	HIV Disease: From Cause to Cure	Ho DD	Montefiori: Ab VIMC
Bispecific Antibodies	Keystone Symposium: HIV Vaccines, Olympic Valley, California	Ho, D.D.	Montefiori: Ab VIMC
Development of Ibalizumab and Improved Variants for Passive Immunization Against HIV	AIDS Vaccine 2011 - Bangkok	Ho, DD
Engineering Antibodies with Potent and Broad Inhibitory Activity against HIV	PEGS Boston, MA	Ho, DD	Montefiori: Ab VIMC
Profound Increase in HIV-1 Envelope Incorporation into Virions Mediated by Genetic Modification of the Cytoplasmic Tail of Envelope	AIDS Vaccine 2013, Barcelona, Spain	Hogan, Michael J.
Murine B cells that bind to neut 2F5 MPER epitope frequent in immature B-cell compartment, undetect in mature splenic pools	AIDS Vaccine 2007 - Seattle	Holl, T
Generation of Robust Antibody Responses to HIV-1 Membrane Proximal External Region (MPER) Antigens	AIDS Vaccine 2008, Cape Town	Holl, TM
Generation of Antibody Responses to HIV-1 Membrane Proximal External Region (MPER) Antigen	AIDS Vaccine 2009, Paris	Holl, TM
Genetic Components of Env Sensitivity to Neutralizing Antibodies	20th International HIV Dynamics & Evolution, 2013, The Netherlands	Hraber, P.	Self: VISC
Profiles of neutralizing antibody responses in chronically HIV-1 clade B’ infected treatment-naïve former plasma donors in China	AIDS Vaccine 2010, Atlanta	Hu, X.
Profiles of Neutralizing Antibody Responses in Chronically HIV-1 CRF07_BC Infected Intravenous Drug Users in Western China	AIDS Vaccine, 2011, Bangkok Thailand	Hu, X.
Some Statistical Issues in the Analysis of Vaccine-induced Immune Response Biomarkers	Department of Biostatistics, University of Washington, Seattle, WA	Huang Y
Passive Immunization Approaches to HIV Prevention	Antibodies as Drugs: Immunological Scaffolds as Therapeutics, Banff, Canada	Huang Y	Montefiori: Ab VIMC
Statistical Design and Analysis of the CAVD-VIMC Elispot Transfer Study 001	AIDS Vaccine 2009, Paris	Huang, Y	Self: VISC
Adjusting for inter-laboratory variability via integration of paired-sample data to correct for measurement error	Department of biostatistics, University of Washington, Seattle, WA. February, 2012	Huang, Y
Crystal structure of the neutralizing antibody HK20 in complex with its gp41 antigen	AIDS Vaccine 2010, Atlanta	Hulsik, David Lutje
CFAR: Support for EUROPRISE, a legacy for HIV/AIDS research	EUROPRISE Annual Conference 2011	Hurley Matthew
Programme EVA Centre for AIDS Reagents (CFAR).	Society for General Microbiology Spring 2010 Meeting, Edinburgh, 29 March – 01 April 2010.	Hurley, M.
Programme EVA Centre for AIDS Reagents (CFAR)	Health Protection 2010 Conference, Warwick, 14-15 September 2010	Hurley, M.
RFID for anonymous biological samples and pseudonyms.	Proc. IEEE International Conference on RFID-Technology and Applications (RFID-TA), Sitges, Barcelona, Spain: 368-372	Ihmig, F
Development of electronic cryovials and electronic cryotank modules for the "Global HIV Vaccine Research Cryorepository"	WOLTE 2008 - Ilmenau, Germany	Ihmig, FR
Robust Broadly Neutralizing Antibody Responses in a Subset of HIV-1-Infected Individuals in Chennai, India: Potential Avenues for Vaccine Design	IAS Conference, Vienna, July 2010	Iqbal, HS
Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients	AIDS Vaccine 2009, Paris	Isaksen, A
Expansion of the Current Concept of Proficiency Testing for Use as a Learning Tool	SQA Annual Meeting, Grapevine, TX	Itani, E.	Gottardo: VISC
Comparative Viral Genome Visualization (Poster)	IEEE Information Visualization Conference (IEEE InfoVis) - Atlantic City	Jen, D
Strong and potent neutralizing IgG memory B cells in HIV-1 subtype C and CRF02_AG infected individuals	AIDS Vaccine 2009, Paris	Jhagjhoorsingh, SB
Next-generation Sequencing for HLA Typing and MHC Sequence Interrogation for Host Genetics of HIV Infection	CROI 2010, San Francisco	Jia, X
Structural Basis of the Antibody-Antigen Interaction in Human Anti-V3 HIV-1 Monoclonal Antibodies	AIDS Vaccine 2008, Cape Town	Jiang, X
Crystal Structures of HIV-1 Neutralizing Anti-V3 Monoclonal Antibody 2557 in Complex with V3 Peptides	AIDS Vaccine 2007 - Seattle	Jiang, X
Molecular design of a mimotope that preserves conserved structural elements of the HIV-1 V3 crown	AIDS Vaccine 2009, Paris	Jiang, Xunqing
Increased HIV-1 Immunogenicity of Replication Competent NYVAC	AIDS Vaccine	Jonathan Heeney	Montefiori: Ab VIMC;#Koup: T Cell VIMC;#Self: VISC
Rapid Appearance of Vaccine-Induced Potentially Protective anti-Env Antibody Responses with Early Co-Administration of Bivalent gp120 in Combination with NYVAC or DNA	AIDS Vaccine	Jonathan Heeney	Koup: T Cell VIMC;#Montefiori: Ab VIMC;#Self: VISC
Differential detection of HIV-1 Env neutralization in two standardized assays – implications for vaccine immune correlates analysis	Keystone Symposium, HIV Vaccines (X8)	Jones, J.	*Other
Polyvalent Gag-specific CD8 T-cells with enhanced functional properties are enriched in HIV-1 clade C infected individuals with lower viral loads	AIDS Vaccine 2009, Paris	Julg, B
HLA Class II Allele DRB1*1303 Is Associated with Reduced Viral Loads in 2 Independent Cohorts of Different Ethnicity and HIV Clades of Infection	CROI 2010, San Francisco	Julg, B
Novel VSV-SIV Chimeric Vaccine Candidates	Keystone - Immunologic mechanisms of vaccination, 2010, Seattle WA	Jurgens, Christy
"RFID system for the identification of biological samples"	Electronics System Integration Technology Conferences ESTC 2010, Berlin Germany, 13-16 Sep	Karim Hichri
"RFID system for the identification of biological samples"	Electronics System Integration Technology Conferences ESTC 2010, Berlin Germany, 13-16 Sep	Karim Hichri
Magnitude and Breadth of the Neutralizing Antibody Response in RV144	Institute of Human Virology 12th Annual International Meeting	Karnasuta, C.
Neutralizing Antibody Responses in Key HIV-1 Vaccine Trials.	Vaccine & ISV Annual Global Conference, 2011, Seattle Washington	Karnasuta, C.
Magnitude and Breadth of the Neutralizing Antibody Response in RV144	AIDS Vaccine 2010, Atlanta	Karnasuta, Chitraporn
Programming the magnitude and durability of HIV-1 env specific humoral immunity in Rhesus Macaques using novel TLR4 and TLR7/8 ligands	33rd Annual Symposium on Nonhuman Primate Models for AIDS, Monterey, CA	Kasturi, Sudhir Pai
Mucosal trafficking and differentiation of vaccine-elicited CD8+ T-lymphocytes	AIDS Vaccine 2009, Paris	Kaufman, DR
Unique spectrum of pro-and anti-inflammatory molecules induced on DCs by simultaneous stimulation with TLR8 plus TLR3 or TLR4 ligands	AIDS Vaccine 2008, Cape Town	Kavanagh, DG
Replication competent attenuated strains of vaccinia virus as potential vaccine vectors.	AIDS Vaccine 2008, Cape Town	Kibler, K
Improvement of the HIV/AIDS vaccine candidate NYVAC-C by deletion of the viral type I IFN inhibitor and/or acquisition of replication competence	AIDS Vaccine 2010, Atlanta	Kibler, K.
Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines	Poxvirus 2010	Kibler, K.V.
Construction and characterization of replication competent attenuated NYVAC-based vectors as potential HIV vaccines	AIDS Vaccine 2009, Paris	Kibler, KV
Biophysical Dissection of the Antigen-Antibody Interaction of the Broadly Reactive Anti-V3 Human mAb 447-52D	AIDS Vaccine, 2012, Boston	Killikelly, April
Examination of size and avidity in the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10	Keystone 2009	Klein, JS
Enteric adenovirus 41 vector enhances induction of intestinal cellular immunity by oral priming	International Congress of Mucosal Immunology 2009 - Boston	Ko, SY
Development of recombinant adenovirus 28 vectors for HIV vaccines	AIDS Vaccine 2009, Paris	Ko, SY
Recombinant simian adenovirus vectors for the development of alternative Ad5 HIV vaccines	AIDS Vaccine 2010, Atlanta	Ko, SY
Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment	German Society for Virology 2009 - Leipzig	Koch, S	Montefiori: Ab VIMC
Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment	AIDS Vaccine 2008, Cape Town	Koch, S	Montefiori: Ab VIMC
Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment	19th Annual Meeting of the Society for Virology 2009 - Leipzig	Koch, S	Montefiori: Ab VIMC
Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment	IAS 2009 - Cape Town	Koch, S	Montefiori: Ab VIMC
First implementation of an automated cell culture and transfection system for HIV-1 Env-pseudotyped virus production	AIDS Vaccine 2010, Atlanta	Koch, S.	von Briesen: HSC
“First implementation of an automated cell culture and transfection system for HIV-1 Env-pseudotyped virus production”	AIDS Vaccine 2010, Atlanta	Koch, S.	Montefiori: Ab VIMC
Llama antibody fragments that recognise gp41 of HIV-1 envelope glycoproteins	AIDS Vaccine 2010, Atlanta	Koh, Willie
Fusion Peptide of HIV-1 as a Site of Vulnerability to Neutralizing Antibody	Keystone HIV Vaccines	Kong R
Epitope Mapping of Neutralizing Antibody 1.7A on the Human Immunodeficiency Virus Type 2 gp160 Glycoprotein	CROI 2009 - Montreal	Kong, R
Structures of human mAb 2909 and rhesus mAb 2.5B that target quaternary structure-dependent neutralizing epitopes of HIV-1 gp120	AIDS Vaccine 2010, Atlanta	Kong, Xiang-Peng
Multiparametric Flow Analysis of HIV-specific CD8 T-cell Mediated Virus Inhibition	Keystone 2010, Banff Canada	Kopycinski, J
HIV-1 Vaccine Design based on Human Vaccine Trials to Improve Gag, Pol, Nef and Env Specific Immune Responses	AIDS Vaccine 2009, Paris	Köstler, J
Effects of V3 Variation and V1-V2 Masking on Neutralization on a Panel of Tier 2 Clade B Envs by V3-Specific MAbs and PAbs	AIDS Vaccine 2007 - Seattle	Krachmarov, C
Highly Complex Neutralization Determinants on a Monophyletic Lineage of Newly Transmitted Subtype C HIV-1 Env Clones from India	AIDS Vaccine 2008, Cape Town	Kulkarni, S
Structure-guided Modification and Optimization of Antibody VRC07	AIDS Vaccine 2012	Kwon Y
new technologies to better understand spontaneous control of HIV (Oral Presentation)	Unlocking the Mystery of the HIV Controller Symposium 2009 - San Francisco	Kwon, D
The Role of CD4+ CD25+ Regulatory T Cells in the Control of IL-10 Mediated T cell Impairment in Chronic HIV Infection	AIDS Vaccine 2009, Paris	Kwon, DS
Identification of amino acid residues in HIV-1 envelope targeted by plasma broadly neutralizing antibodies using evolutionary models	AIDS Vaccine, 2011, Bangkok Thailand	Lacerda, M.
Neutralizing antibody responses to HIV-1 are dependent on conformational integrity of gp140 immunogens	AIDS Vaccine 2010, Atlanta	Lai, Rachel P.J.	Montefiori: Ab VIMC
Mutations of V2 C-strand residues controlling the Env trimer conformation drive the maturation of V2-apex broadly neutralizing antibodies	Keystone HIV Vaccines	Landais E
Efficacy of an Engineered Bispecific Anti-HIV Antibody in Humanized Mice	CROI 2016, Boston, MA	Lanzi, A.	Montefiori: Ab VIMC
The Memory B Cell and Serum Antibody Repertoire Share Clonal Lineage Members of HIV-1 gp41 Broadly Neutralizing Antibodies	2016 Keystone	LaTonya Williams	Montefiori: Ab VIMC
The intracellular production of HIV antigenic peptides is guided by predictable motifs and can be altered: implications for immunogen design	AIDS Vaccine 2009, Paris	Lazaro, E
Predictable motifs guide the intracellular production of HIV antigenic peptides	HIV Acute Infection Meeting 2009 - Boston	Lazaro, E; Zhang SC
Structure, dynamics and antigenicity in HIV Env probed by HDX-MS	Keystone Structural Analysis of Supramolecular Assemblies by Hybrid Methods (C1)	Lee, Kelly K.
The Cryo-Brehm Project: A Prototype of a Living Biological Encyclopaedia”.	8th International Conference on Behaviour, Physiology and Genetics of Wildlife	Lermen D
Targeting HIV Env gp140 to LOX-1 in combination with replication competent NYVAC-C Elicits Humoral and Cellular Responses in Rhesus Macaques	AIDS Vaccine	Levy Yves	Pantaleo: RepliVax Vaccine Platform
. Targeting HIV Env gp140 to LOX-1 in combination with replication competent NYVAC-C Elicits Humoral and Cellular Responses in Rhesus Macaques.	AIDS Vaccine	Levy Yves
Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injections. Results of the EV03/ANRS Vac20 Phase I/II Trial.	AIDS Vaccine 2010, Atlanta	Levy, Y
Reduced replication capacity of NL4-3 chimeric viruses encoding RT-Integrase sequences from HIV-1 elite controllers (poster)	AIDS Vaccine 2009, Paris	Li, C
Molecular Cloning and Biological Characterization of Full Length Transmitted/ Founder Viruses from Injection Drug Users (IDU), Men Who have Sex with Men (MSM) and Heterosexuals (HSX)	CROI 2010, San Francisco	Li, H
Threshold Mutation Rate Is Required for V3 Antibodies Displaying Cross-Neutralization of HIV-1 Tier 2 Viruses	AIDS Vaccine - Barcelona, Spain	Li, L.	Montefiori: Ab VIMC
Characterization of the Plasma Cell Repertoire in Acute HIV-1 Infection (AHI)	AIDS Vaccine 2009, Paris	Liao, HX
Design of a Recombinant HIV-1 Envelope Construct That Binds With High Affinity To Antibodies That Recognize Linear, Conformational and Broadly Neutralizing Epitopes Within V1/V2.	AIDS Vaccine, Boston, MA	Liao, Larry
Recombinant Baculovirus Derived HIV-1 Virus-Like Particles Elicit Potent Neutralizing Antibody Responses	AIDS Vaccine 2007 - Seattle	Liu, W	Montefiori: Ab VIMC
Analysis of neutralizing antibody responses induced by gp120 DNA prime followed by monovalent or polyvalent V3 epitope boost	AIDS Vaccine 2010, Atlanta	Lu, Shan	Montefiori: Ab VIMC
A novel high-throughput platform to generate gp120-specific rabbit monoclonal antibody from single B cells	Keystone Symposia: HIV Vaccines - Adaptive Immunity and Beyond, Banff, Canada, March 9th - 14th, 2014	Lu, Shan
HIV-1- specific Env memory B cell and V1/V2-specific antibody responses were generated by a the polyvalent DNA prime-protein boost HIV vaccine, DP6-001, in a phase I clinical trial	Keystone Symposia: HIV Vaccines - Adaptive Immunity and Beyond, Banff, Canada, March 9th - 14th, 2014	Lu, Shan
Evidence on the involvement of germinal centers and T follicular helper cells in DNA immunization for HIV vaccine development	Keystone Symposia: HIV Vaccines - Adaptive Immunity and Beyond, Banff, Canada, March 9th - 14th, 2014	Lu, Shan
Immunological and structural analyses of R53, a new broadly reacting CD4-blocking rabbit mAb	Keystone Symposia: HIV Vaccines - Adaptive Immunity and Beyond, Banff, Canada, March 9th - 14th, 2014	Lu, Shan
In Vivo Targeting of HIV Gag to Dendritic Cells in Combination with Poly ICLC Is Safe and Immunogenic in Healthy Volunteers	AIDS Vaccine 2012	M. Caskey	Montefiori: Ab VIMC
Programme EVA Centre for AIDS Reagents (CFAR)	Health Protection 2010 Conference, Warwick, 14-15 September 2010.	M. Hurley
Programme EVA Centre for AIDS Reagents (CFAR)	Society of General Microbiology, 2010 Spring Meeting (30 March – 01 April 2010)	M. Hurley
Programme EVA Centre for AIDS Reagents (CFAR)	Health Protection Agency Annual Conference (14-15 September 2010)	M. Hurley
Characteristics of HIV-1 gp120 Molecules That Bind Ancestor, Intermediate and Mature Forms of VRC01- like Antibodies	AIDS Vaccine 2012	M. Joyce
Enumeration of antigen-specific B cell responses by flow cytometry for monitoring vaccine immunogenicity	Keystone 2013	Ma, Steven
VPhaser: Detecting Rare Variants in Mixed Viral Populations from ultra-deep Sequence Data	CROI, 2011, Boston, MA	Macalalad, A
Development of intra- and inter-subtype cross-neutralizing antibodies in HIV-1 subtype C infection	IAS 2009 - Cape Town	Madiga, M
Evolution of cross-neutralizing antibodies in HIV-1 infection	AIDS Vaccine 2010, Atlanta	Madiga, M.
Implementing the TZM-bl cell-based HIV-1 neutralizing antibody assay at the Johannesburg Regional Laboratory of the CAVD/CA-VIMC.	South African AIDS Conference	Madiga, M.
Immune signals can modulate IgG glycosylation to induce stronger antibody effector functions	CAVD - March 2013, Online	Mahan A
Antibody effector function is regulated by a combination of adaptive and innate signals	AIDS Vaccine, Boston MA	Mahan, Alison
Adjuvants modify antibody effector function	AIDS Vaccine, Barcelona, Spain	Mahan, Alison
Antibody glycosylation can be transiently altered after vaccination against HIV	AIDS Vaccine, Barcelona ,Spain	Mahan, Alison
IgG glycosylation in HIV infection predicts antibody effector functionality	Keyston HIV Pathogenesis, Banff, Canada	Mahan, Alison
Glycosylation of IgG by B cells is regulated by immune stimuli	Society for Glycobiology, San Diego CA	Mahan, Aliston
Phenotypic variation and neutralization sensitivity in acute HIV-1 infection	Europrise Annual Conference, Budapest, Hungary, 2009	Mainetti L
Capturing intra-host diversity of viral genomes using “next-generation” sequencing technology	Next-Generation Sequencing Data Analysis 2009 - Providence RI	Malboeuf, C
HIV-activated plasmacytoid dendritic cells induce regulatory T cells through an indoleamine 2,3 dioxygenase dependent mechanism	AIDS Vaccine 2008, Cape Town	Manches, O
HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism	AIDS Vaccine 2009, Paris	Manches, O
Mucosal trafficking of vector-specific CD4+ T lymphocytes following Adenovirus serotype 5 vaccination of rhesus monkeys.	Keystone 2010	Masek-Hammerman, K
Impact of Antibody Epitope and Subclass on Monocyte Phagocytosis of Infectious HIV-1 Virions	Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery 10th Anniversary Meeting	Matthew Zirui Tay
Impact of Rare Adenovirus Seroprevalence on HIV-1 Acquisition in the Step Study	AIDS Vaccine 2009, Paris	Maxfield, LF	McElrath: Innate to Adaptive Immunity
Analysis of the Dimerization Initiation Sequences of Concorant and Discordant Viral Variants Superinfecting HIV-1 Patients	AIDS Vaccine 2010, Atlanta	Mayr, Luzia
Potent HIV neutralizing rabbit antibodies elicited by SOSIP trimer immunization converge on a shared epitope	Keystone HIV Vaccines	McCoy L.E.
Broad and Potent Neutralization of HIV-1 by Human-Llama Fusion Antibodies Derived from Immunized Llamas	AIDS Vaccine, Boston, MA USA	McCoy, L.E.	Montefiori: Ab VIMC
Vaccine-Induced Immunity in T-Cell Based Candidate HIV Vaccines	AIDS Vaccine 2008, Cape Town	McElrath, MJ
A native-like HIV-1 envelope trimer from clades A, B and C that engages multiple germline precursors of broadly neutralizing antibodies	Keystone HIV Vaccines	Medina-Ramirez M
Programme European Vaccine against AIDS (EVA) – A strategic initiative to accelerate global access to HIV/AIDS research materials	16th International Symposium on HIV and Emerging Infectious Diseases (24-26 March 2010)	Meghna Ramaswamy
HIV Gp120 Epitope Profile on Cell-Bound Virions Assessed using Various Microscopy Techniques	17th Annual International Meeting of the Institute of Human Virology, Baltimore, MD	Mengistu M	Lewis: Ab Specificity & Fc-Mediated Protection
CD4-Induced Epitopes Are Exposed on Cell-Bound HIV-1: Potential Targets for Fc Receptor Mediated Humoral Immunity	AIDS Vaccine 2013, Barcelona, Spain	Mengistu, Meron
The "Global HIV Vaccine Research Cryorepository": Standardized HIV-1 Env-pseudovirus production under GCLP conditions allows highly concordant global HIV neutralizing antibody assessment	German-Japanese AIDS Konferenz 2009 - Bochum	Meyerhans, A	Montefiori: Ab VIMC
Mutations in the HIV-1 Env Cytoplasmic Tail that Increase Cell Surface Expression Enhance the Neutralizing Antibody Response in Prime-Boost Vaccination	Keystone HIV Vaccines Conference in Banff, Alberta, Canada	Michael Hogan	Montefiori: Ab VIMC
Tier 1 Strains of HIV-1: Time to Break an Old Habit?	HIVR4P, Chicago, IL	Montefiori, D.
Standardized Assessments of HIV Vaccine-Elicited Neutralizing Antibodies	Keystone Symposium, HIV Vaccines	Montefiori, D.C.	*Other
Statistical Approaches to Analyze Multi-parametric Flow Analysis	BioIT Conference 2008 - Vancouver	Moodie, Z
Anti-lipid Human Monoclonal Antibodies Inhibit HIV-1 Infection of PBMC By Binding to Host Cells	AIDS Vaccine 2008, Cape Town	Moody, MA
Improved immunogenicity against HIV-1 clade C antigens by using NYVAC-C with restored replication competence.	AIDS Vaccine 2010, Atlanta	Mooij, P
Immunisation with recombinant HLA class I and II, HIV-1gp140 and SIVp27 antigens elicits protection against SHIV-SF162P4 infection in rhesus macaques	AIDS Vaccine 2009, Paris	Mörner A
A Large-Scale Analysis of Immunoglobulin Sequences Derived From Plasmablasts/Plasma Cells in Acute HIV-1 Infection Subjects	AIDS Vaccine 2009, Paris	Munshaw, M
A Large-Scale Analysis of Immunoglobulin Sequences Derived From Plasmablasts/Plasma Cells in Acute HIV-1 Infection Subjects	Multi-Scale Modeling of Host/Pathogen Interactions 2009 - Pittsburgh	Munshaw, S
Development of a luciferase based viral inhibition assay to evaluate vaccine induced HIV specific CD8 T-cell responses	MASIR	Naarding Marloes	Montefiori: Ab VIMC
AIDS Vaccine Clinical Evaluation: Where Are We and Where Can We Go?	AIDS Vaccine 2009, Paris	Nabel, Gary J.
Prospects for a Global AIDS Vaccine	AAAS Meeting 2008 - Boston	Nabel, GJ
No Evidence for Consistent Virus-specific Immunity in Simian Immunodeficiency Virus Exposed, Uninfected Rhesus Monkeys.	2007 Annecy	Nabel, GJ
Criteria for Advancement of Novel Vaccine Candidates	Keystone 2008 - Banff	Nabel, GJ
Structural Analysis of the Unmutated Ancestor of the HIV-1 Envelope V2 Region Antibody CH58 Isolated from an RV144 Vaccine Efficacy Trial Vaccinee	Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery 10th Anniversary Meeting	Nathan Nicely
Structural Analysis of the Unmutated Ancestor of the HIV-1 Envelope V2 Region Antibody CH58 Derived Isolated from an RV144 HIV-1 Vaccine Efficacy Trial Vaccinee and Associated with Decreased Transmission Risk	Duke Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery 9th Anniversary Meeting 2014	Nathan Nicely
Mosaic HIV-1 Gag antigens can accurately present major HIV-specific epitopes in human cells.	AIDS Vaccine 2010, Atlanta	Ndhlovu, Z
T Cell Immunity in Acute HIV Subtype C Infection, Implications for the Development of an Effective AIDS Vaccine	Immunochemistry and Immunobiology Gordon Research Conference, Newry, ME, USA	Ndhlovu, Zaza
Massive activation, expansion and subsequent apoptosis of CD8 T cells in acute HIV infection	HIV R4P, Cape Town, South Africa	Ndhlovu, Zaza
HIV elite controllers: A model for T cell vaccination of functional cure	Animal and Human Vaccine Development in South Africa: Past Achievements and Future Prospects, Pretoria, South Africa	Ndhlovu, Zaza
Crystal structure of a non-neutralizing antibody to the HIV-1 gp41 membrane proximal external region	AIDS Vaccine 2010, Atlanta	Nicely, Nathan
Characterization of genotypic properties of transmitted HIV-1 variants across different subtypes	AIDS Vaccine 2008, Cape Town	Nofemela, A
Genetic characterization of transmitted HIV-1 env variants from Mbeya, Tanzania	Abstract: 3rd Annual South African AIDS Conference, 2009, Durban	Nofemela, A
The entry efficiency of transmitted HIV-1 variants from Mbeya, Tanzania plays a role in disease progression	AIDS Vaccine 2010, Atlanta	Nofemela, A.
MHC class I chain-related protein A shedding in chronic HIV-1 infection is associated with profound NK cell dysfunction	AIDS Vaccine 2009, Paris	Nolting, A
Neutralizing Antibody Response to HIV	CROI 2011 - Boston	Nussenzweig, M
Novel recombinant vaccines based on replication-defective flavivirus vectors expressing HIV immunogens.	American Society for Virology 34th Annual Meeting, London, Ontario, Canada	Oakes BH,
B cell depletion, CD4 counts and viral load impact on ADCC, binding antibodies and neutralizing antibody profiles in HIV-1 subtype A chronically infected Ugandans	AIDS Vaccine 2010, Atlanta	Oballah, P.
B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 count, viral load and humoral immune responses.	AIDS Vaccine, 2011, Bangkok Thailand	Oballah, P.
Development of New Virologic Reagents: Improved Immune Monitoring Tools and Assays	AIDS Vaccine 2010, Atlanta	Ochsenbauer, C.
Novel SIVmac239-based Replication Competent Luciferase Reporter Viruses	Keystone Symposia, Banff Alberta Canada	Ochsenbauer, C.	*Other
Impact of CTL Escape Mutations in HIV-1 Nef on Viral Replication.	AIDS Vaccine 2009, Paris	Oniangue-Ndza C
Impact of CTL Escape Mutations in HIV-1 Nef on Viral Replication (poster)	AIDS Vaccine 2009, Paris	Oniangue-Ndza, C
Nature of Synergistic ADCC Activity Mediated by Human Monoclonal Antibodies (mAbs) Against HIV-1 Env	AIDS Vaccine 2013, Barcelona, Spain	Orlandi, Chiara
Evolution of Autologous Neutralizing Antibody Responses in Subjects Infected with HIV-1 Subtype D in Rakai District, Uganda	Keystone 2009	Ouma, B
Riding the Technology Wave: Implementing Electronic Laboratory Notebooks in a GCLP-compliant Academic Environment	SQA Annual Meeting, Grapevine, TX	Ozaki, D.	*Other
Development of a Quality System for a Protein Production Facility at an Academic Institution	Society of Quality Assurance Annual Meeting, 2013, Indianapolis IN	Ozaki, D. A.	Haynes: Protein Expression Facility
Bringing Academic Research and Development Laboratories to Perform GCLP-compliant studies for Human Clinical Trials: A challenge for assay implementation and revalidation	AIDS Vaccine 2009, Paris	Ozaki, Daniel A.
Bringing Academic Research and Development Laboratories to Perform GCLP-compliant studies for Human Clinical Trials: A challenge for assay implementation and revalidation	Society for Quality Assurance Annual Meeting –Apr 2010 - Cincinnati, OH	Ozaki, Daniel A.
CryoEM studies of ground and CD4-induced open states of HIV-1 Env SOSIP gp140 trimers	Keystone HIV Vaccines	Ozorowski G
Boosting of replication competent NYVAC primed HIV-1 specific T-cell responses by HIV synthetic long peptides (SLP)	AIDS Vaccine 2011	P. Mooij
PG9-iMab: A Bispecific Antibody with 100% Breadth and Picomolar Potency Against HIV-1	3rd Annual Bispecific Antibody Summit, 2012, Boston, MA	Pace CS	Montefiori: Ab VIMC
Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Exceptional Breadth and Potency against HIV, which Adopts a Unique Pathway to Resistance	CROI 2011 - Boston	Pace, C and Fordyce, M	Montefiori: Ab VIMC
PG9-ibalizumab and VRC01-ibalizumab bispecific fusion antibodies exhibit essentially 100% breadth, picomolar potency and synergistic mechanism of action	AIDS Vaccine 2011 - Bangkok	Pace, CS	Montefiori: Ab VIMC
Engineering Bispecific Antibodies for HIV Prevention	HIV R4P, Capetown, South Africa	Padte NN	Montefiori: Ab VIMC
Immune Correlates of Protection to HIV	Keystone 2009	Pantaleo, G
Using Ubiquitin Fusion to Augment Immune Responses Against HIV-1 Antigens	AIDS Vaccine 2008, Cape Town	Papagatsias, T
Using Ubiquitin Fusion to Augment Immune Responses Against HIV-1 Antigens	AIDS Vaccine 2009, Paris	Papagatsias, T
Developing an Anti-HIV Vaccine Using Nucleoside-Modified mRNA Encoding Envelope	AIDS Vaccine 2013, Barcelona, Spain	Pardi, Norbert
DEVELOPMENT OF LIVE VSV VECTORS FOR DELIVERY OF AIDS VACCINES.	14th International NegativeStrand Virus Meeting, 2010, Bruges, Belgium	Parks, Christopher, L
DEVELOPMENT OF VSV VECTORS FOR DELIVERY OF ENV IMMUNOGENS.	AIDS Vaccine 2010, Atlanta	Parks, Christopher, L
Design and characterization of stabilized SHIV SOSIP trimers to assess in vivo protection from di cult-to-neutralize SHIV isolates	Keystone HIV Vaccines	Pauthner M
Structural definition of new transitional epitopes exposed by CD4 binding to HIV-1	14th Annual International Meeting of the Institute of Human Virology	Pazgier, Marzena	Haynes: Broad Neutralizing Antibody Consortium
Different Memory T Cell Phenotypes Are Elicited by Ad5 and Rare Adenoviruses	AIDS Vaccine 2012, Boston	Penaloza, Pablo	Barouch: Replicating Adenovirus Vectors
Biovalent NYVAC-based Vaccine Candidates against HIV/AIDS Expressing Clade C Trimeric Soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs	HIV Research for Prevention 2014	Perdiguero, Beatriz
Epitope specific CD8+ T-cell responses predict spontaneous HIV virus replication	AIDS Vaccine 2008, Cape Town	Pereyra, F
Association between Delayed HIV-1 Entry and Increased Neutralization Sensitivity in A3R5 Cells	Keystone Symposium, HIV Vaccines	Perez, L.G.
Env Binding to the ɑ4β7 Integrin Complex is not a General Property of Most HIV-1 Variants	AIDS Vaccine, Barcelona Spain	Perez, Lautaro G.
Effector memory T-cell targeted vaccines	Keystone Symposia, HIV Vaccines: Adaptive Immunity and Beyond, Banff, Canada	Picker, Louis J.	Bill and Melinda Gates Foundation;#Picker: An Attenuated CMV Vector
Persistence Pays Off: Stringent control and potential clearance of AIDS virus infection by persistent vaccine-induced effector memory T cells	AIDS 2012 Vaccine, Symposium 05: Mucosal Immunity, Boston	Picker, Louis J.	Bill and Melinda Gates Foundation;#Picker: An Attenuated CMV Vector
High titers of cross-clade ADCC-mediating antibodies are detectable in plasma samples collected from individuals with broadly neutralizing antibodies	AIDS Vaccine 2010, Atlanta	Pollara, J.
Ontogeny, breadth, and specificity of circulating ADCC-mediating antibodies in HIV-1 infected individuals	AIDS Vaccine, 2011, Bangkok Thailand	Pollara, Justin
Vaccine-induced ADCC-mediating antibodies target unique and overlapping envelope epitopes	AIDS Vaccine	Pollara, Justin	Montefiori: Ab VIMC
Breadth and Specificity of ADCC Antibodies Induced by Infection and Vaccination	Keystone Symposium 2012 “HIV Vaccines”	Pollara, Justin	Montefiori: Ab VIMC
Differential Effectiveness of Poly I:C as an Adjuvant for Priming and Boosting Human CD8+ T cell Responses	Keystone Symposia - Immunological Mechanisms of Vaccination, 2010, Seattle	Pufnock, Jeff
RepliVax: A novel single-cycle vaccine approach to flavivirus and non-flavivirus targets.	15th annual World Vaccine Congress, Washington DC	Pugachev K
Innate control of adaptive immunity to vaccines and pathogens	AIDS Vaccine 2009, Paris	Pulendran, B
Skewed HIV-1-specific CD4+ Th2 helper cell contribution in progressive HIV-1 infection	AIDS Vaccine 2009, Paris	Pyo, A
Improved vaccinia virus vectors for vaccination against HIV.	AIDS Vaccine 2010, Atlanta	Quakkelaar, E.D.
Enhanced expression of HIV antigens and improved antigen presentation after infection with replication competent attenuated vaccinia virus in vitro	AIDS Vaccine 2009, Paris	Quakkelaarm ED
ISCOMatrix Formulated with Poly I:C Induces Potent Th1 Responses and Enhances Cross-Priming of CD8+ T cells	Keystone Symposia - Immunological Mechanisms of Vaccination, 2010, Seattle	Quinn, Kylie, M.
Partial Germline Reversions Can Increase VRC07 Potency and Breadth	AIDS VAccine 2012	R. S. Rudicell
Increasing Neutralization Resistance Over the Course of the HIV-1 Subtype C Southern African Epidemic	9th International Workshop on HIV Transmission, Cape Town, South Africa	Rademeyer, C.
Applying Synthetic Biology Principles for Better Vaccines: Challenging HIV	CASConference Synthetic Biology, 23 - 25 July 2012, Biocenter of the LMU Munich	Ralf Wagner
Programme European Vaccine against AIDS (EVA) Centre for AIDS Reagents (CFAR) - A Reagent Resource for HIV and other Infectious Diseases	ISHEID, 2010, Marseilles	Ramaswamy, M
A Reagent Resource to facilitate Vaccine and Microbicide Discovery and Development	EUROPRISE, 2009, Budapest	Ramaswamy, M
Programme EVA Centre for AIDS Reagents: A Resource for Research and Reference Reagents and Materials Sharing	AIDS Vaccine 2009, Paris	Ramaswamy, M
Programme EVA Centralised Facility for AIDS Reagents (CFAR)	ISHEID, 2010, Marseilles	Ramaswamy, M.
Marked differences in the immunodominance pattern of HIV-1-specific CD4+ T cell responses in subjects spontaneously controlling HIV-1 infectio	AIDS Vaccine 2010, Atlanta	Ranasinghe, S
Characterization of the membrane proximal domain from HIV gp41 coat protein in detergent micelles with multi-dimensional NMR	World Wide Magnetic Resonance Conference	Reardon, P.
Characterization of a membrane anchored HIV MPER peptide with multi-dimensional NMR	ENC, April 2010, Florida	Reardon, P.N.
NMR structure of an antigenic membrane-associated trimeric MPER domain of HIV envelope gp41	The 25th Anniversary Symposium of The Protein Society, 2011, Boston, MA	Reardon, Patrick N.
Neutralization of HIV-1 cell-cell spread	Keystone 2009	Ren, Li
Improved Protocol for Amplification from Plasma and Cloning of Functional Full-length Envelopes of Different Genetic Forms of HIV-1	CROI 2009 - Montreal	Revilla, A
Development of a panel of functional HIV-1 subtype G full-length envelope clones obtained from plasma of infected individuals	International AIDS Society 2009 - Cape Town	Revilla, A
Construction and Phenotypic Characterization of Functional Envelope Clones Derived from HIV-1 Subtype A Viruses Circulating in Russia	AIDS Vaccine - Barcelona, Spain	Revilla, A.
Adaptive immune responses elicited by recombinant adenovirus vectors exhibit partial MyD88 dependence	AIDS Vaccine 2009, Paris	Rhee, EG
Epitope mapping of HIV-specific CD8+ T cell responses by polyfunctional flow cytometry and proliferation responses reveal distinct specificity defined by function	AIDS Vaccine 2009, Paris	Richmond, M
Human and Rhesus MAbs Recognizing Distinct Groups of Epitopes that Elicit Neutralizing Antibodies against Autologous HIV-1 Strains	AIDS Vaccine 2008, Cape Town	Robinson, JE
Human and Rhesus MAbs Recognizing Distinct Groups of Epitopes that Elicit Neutralizing Antibodies against Autologous HIV-1 Strains	AIDS Vaccine 2008, Cape Town	Robinson, JE
Single Cell Transcriptomics: Measuring Quality and Quantity	Keystone 2013	Roederer, Mario
Genetic and Immunological Evidence for a Role of Env-V3 Antibodies in the RV144 Trial	AIDS Vaccine - Barcelona, Spain	Rolland, M.	*Other;#Haynes: B cell Lineage Envelope Design from RV144 Antibodies;#Koup: T Cell VIMC;#Self: VISC
Mucosal IgA: Protection Against SHIV Infection by Passive and Active Immunization	Cent Gardes Conference on HIV Vaccines, Annecy, France	Ruprecht, Ruth M.
Identification and Chemical Synthesis of a Complete Infectious Transmitted HIV-1 Genome	AIDS Vaccine 2008, Cape Town	Salazar, M
Identification of Transmitted/Founder Complete HIV-1 Genomes in Subjects With Acute HIV-1 Infection	AIDS Vaccine 2008, Cape Town	Salazar-Gonzalez, JF
High-resolution crystal structure of the Fv of quaternary neutralizing epitope mAb 2909 reveals atomic details of its antigen-binding site	AIDS Vaccine, 2012, Boston	Sampson, Jared M.
Centre for AIDS Reagents – Provision of Reagents for AIDS Vaccine and Microbicide Research	EUROPRISE Annual Conference	Sarah Gilbert
Centre for AIDS Reagents – Provision of Reagents for AIDS Vaccine and Microbicide Research	Annual Meeting of the European Vaccines and Microbicides Enterprise (15-18 November 2010)	Sarah Gilbert
Evaluation and Recommendations on Good Clinical Laboratory Practice	AIDS Vaccine 2009, Paris	Sarzotti-Kelsoe, M	Koup: T Cell VIMC
Optimization and Validation of the HIV-1 Neutralizing Antibody Assay in A3R5 Cells	AIDS Vaccine, 2012, Boston MA USA	Sarzotti-Kelsoe, M.	*Other
Mechanism of escape from autologous broadly neutralizing anti-CD4 binding site NAbs during HIV-1 infection	Keystone 2011, British Columbia, Canada	Sather, D. Noah
Determinants of Cross-reactive neutralizing antibody responses developed during natural HIV-1-infection	Keystone 2009	Sather, DN
Structural basis of complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies	Keystone Symposia - HIV Vaccines, Keystone, Colorado	Scharf, Louise	Montefiori: Ab VIMC;#Nussenzweig: Discovery & Characterization of bNAbs
Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody	78th Cold Spring Harbor Symposium on Quantitative Biology: Immunity & Tolerance, Cold Spring Harbor, NY	Scharf, Louise	Nussenzweig: Discovery & Characterization of bNAbs
A new site of broad vulnerability on the HIV-1 envelope spike defined by a patient-derived antibody	Keystone HIV Vaccines, Banff, Canada	Scharf, Louise	Nussenzweig: Discovery & Characterization of bNAbs
Structural basis for HIV-1 gp120 recognition by germ-line antibodies	Palm Springs Symposium on HIV/AIDS	Scharf, Louise	Nussenzweig: Discovery & Characterization of bNAbs
Computational Design of Immunogens to ‘Re-elicit’ Neutralizing Antibodies	American Crystallographic Association Meeting 2009 - Toronto	Schief, B
Scaffolding Epitopes to Provide Directed Antibody Responses	IBC's Annual Antibody Engineering and Antibody Therapeutics Meeting, 2011, San Diego CA	Schief, William R.
Computational design of non-HIV protein scaffolds presenting conserved HIV-1 neutralization epitopes	AIDS Vaccine 2006 - Amsterdam	Schief, WR
Advances in Vaccine Scaffolds	CROI 2008 - Boston	Schief, WR
Generation of a HI-viral packaging cell line as scaffolding for a lentiviral display system	AIDS Vaccine 2009, Paris	Schilling, K
Long-term Stability of Compensated CTL Escape Mutations following Acute HIV Infection	AIDS Vaccine 2008, Cape Town	Schneidewind, A
Identification of Subdominant CD8+ Responses Selecting CTL Escape Mutations in Gag that Impair HIV Replication	Keystone 2009	Schneidewind, A
HIV-1 lineage envelope proteins based on viral sequences from elite neutralizers	Keystone HIV Vaccines	Schorcht A
Standardized serum-free cryomedia have minimum cytotoxicity and maintain antigen-specific T-cell response	AIDS Vaccine 2009, Paris	Schulz, J
Development and application of new storage-technologies for effective and secure cryobanking	Medical Physics and Biomedical Engineering 2009 - Manchen	Schulz, JC
Development and application of new storage-technologies for effective and secure cryobanking	Medical Physics and Biomedical Engineering World Congress 2009 - Munich	Schulz, JC
New modular HIV-cryosubstrates for secure and reliable sample identification and DMSO reduction in cryopreserved peripheral blood mononuclear cells	AIDS Vaccine 2008, Cape Town	Schulz. JC
Primary Immunization Influences the Magnitude, Quality and Breadth of Gag Specific T Cell Responses Following an rAd-5 Boost	AIDS Vaccine 2009, Paris	Seder, R
Expression, purification and antigenic characterization of soluble clade A/B heterotrimeric gp140 Envelope glycoproteins from HIV	Keystone 2009	Sellhorn, G
Engineering and characterization of soluble heterotrimeric gp140- Envelope glycoproteins from HIV	Keystone 2007	Sellhorn, G
Engineering, expression and antigenic and immunogenic characterization of novel soluble clade A/B heterotrimeric gp140-Envelope glycoproteins	AIDS Vaccine 2009, Paris	Sellhorn, G
Improved elicitation of anti-HIV neutralizing antibodies by soluble clade A/B heterotrimeric gp140 Env immunogens	Keystone 2011, British Columbia, Canada	Sellhorn, George
A Mutation in HIV-1 gp41 Envelope Membrane Proximal Region Increases Neutralizing Antibody Potency and in the Context of Peptide-Lipid Conjugates Binds to 2F5 mAb more Stably	AIDS Vaccine 2009, Paris	Shen, X	Haynes: Broad Neutralizing Antibody Consortium;#Montefiori: Ab VIMC
Vaccine Induced Epitope Specific Antibodies to the SIV Envelope Are Distinct from Those Induced to the HIV-1 Envelope	AIDS Vaccine, Barcelona, Spain	Shen, X.	*Other;#McElrath: Innate to Adaptive Immunity;#Pantaleo: Poxvirus-Based Vaccine Development;#Shattock: Novel Antigens for Mucosal Protection
A large-scale cryo-electronic system for biological sample banking	WOLTE 2008 - Ilmenau, Germany	Shirley, SG
Computational profiling the epitope-specific human neutralizing antibodies elicited in the	AIDS Vaccine 2010, Atlanta	Shmelkov, Evgeny
Engineering Antibodies to Enhance Activity and Increase Half-life	HIV Research for Prevention 2014 (HIVR4P), Cape Town, South Africa	Sievers, Stuart, A	Nussenzweig: Discovery & Characterization of bNAbs
Compartmentalization of Drug Resistance, Immune Escape, and Co-receptor Tropism in Circulating Plasma Viruses during Late-stage HIV Infection	CROI 2009 - Montreal	Skaria, Amy
Nanoparticle displayed stabilized native-like envelope trimers as immunogens	Keystone HIV Vaccines	Sliepen K
Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface	AIDS Vaccine 2009, Paris	Song, L
Interactions between anti-HIV antibodies and their lipid-embedded epitopes defined by EPR spectroscopy	Biophysical Meeting, Philadelphia, PA, 2013	Song, Likai
Developing the capacity for multifunctional lymphocyte analysis at the UVRI-IAVI laboratory	Uganda AIDS Conference 2008 - Entebbe	Ssemaganda, A
Identification of an HIV-1 Env Panel to define breadth and potency of ADCC responses.	Keystone Symposium, HIV Vaccines	Stanfield-Oakley, S.A.	Gottardo: VISC
Identification of a Panel of IMC to define breadth and Potency of ADCC Responses	CFAR Retreat, Durham, NC	Stanfield-Oakley, Sherry A	*Other;#Self: VISC
A new platform for optimized sample tracking, data collection and data integration for HIV biomaterials	AIDS Vaccine 2010, Atlanta	Stephan Kiefer
Applying a Standard Data Warehouse Star Schema to Multiple Immunologic Assays in an Integrated Data Portal	American Medical Informatics Association, San Francisco, CA	Stofel J
Modulation of Vaccine Induced Humoral Immune Responses by Heterologous T Cell Help	AIDS Vaccine conference, 2013, Barcelona, Spain	Storcksdieck genannt Bonsmann, Michael
Overcoming a bias in the quality of the HIV-1 Env-specific antibody response by intrastructural help	44th Annual Meeting of the German Society for Immunology, Bonn, Germany	Storcksdieck genannt Bonsmann, Michael
Overcoming a bias in the quality of the HIV-1 Env-specific antibody response by intrastructural help	25th Annual Meeting of the Society for Virology, Bochum, Germany	Storcksdieck genannt Bonsmann, Michael	Ackerman/Alter: Leveraging Antibody Effector Function
Impairment of HIV-1-specific CD8+ T cell function by soluble epithelial adhesion molecules	AIDS Vaccine 2009, Paris	Streeck, H
The First Emerging CD8 T Cell Responses Are a Major Determinant of Early Viral Set-Point	CROI 2009 - Montreal, Canada	Streeck, H
Prevalent HLA Class I Allele Combinations Result in a Lack of HIV-1-Specific CD8+ T Cell Responses and Higher Viral Set Point	HIV Acute Infection Meeting, Boston, MA - 2009	Streeck, H
Impairment of HIV-1-specific CD8+ T cell function by soluble epithelial adhesion molecules	AIDS Vaccine 2009, Paris	Streeck, H
Prevalent HLA class I allele combinations result in a lack of HIV-1-specific CD8+ T cell responses and higher viral set point	HIV Vaccine Keystone, Banff, Canada - 2009	Streeck, H
The epithelial adherens junction protein E-cadherin inhibits HIV-1-specific CD8+ T cell responses by binding to KLRG1	International Congress of Mucosal Immunology 2009 - Boston	Streeck, H; Kwon, DS
Masking of MPER Epitopes through Self-Associations	AIDS Vaccine 2009, Paris	Strong, RK
Rational Design of a Novel Bispecific HIV-1-Neutralizing Antibody, iMabm36	CROI 2012 - Seattle	Sun, M	Koup: T Cell VIMC;#Montefiori: Ab VIMC
Fragmentation, ubiquitination and mosaicism of HIV/SIV genetic components in the context of thermo-stable adenoviral (Ad) vectors as novel vaccine approaches against HIV-1/AIDS	Federation of European Biochemical Societies (FEBS), 2010, Gothenburg, Sweden	Takis, A
Rapamycin Treatment Improves The Quality And Quantity Of Ad5 Vaccine Induced CD8 T Cell Responses	Keystone Symposia - Immunological Mechanisms of Vaccination, 2010, Seattle	Tan, Wendy, G
Retinoic acid as an adjuvant to imprint mucosal homing properties to vaccine-induced T cells	American Association of Immunology 2009 - Seattle	Tan, X
Retinoic acid as an adjuvant to imprint mucosal homing properties to vaccine-induced T cells	International Congress of Mucosal Immunology 2009 - Boston	Tan, X
Genetic characteristics of HIV-1 envelope associated with broadly cross-reactive neutralizing antibody responses	AIDS Vaccine 2010, Atlanta	Thebus, Ruwayhida
Phenotypic characterization of a panel of HIV-1 subtype G functional envelope clones	AIDS Vaccine 2010, Atlanta	Thomson, M.M.
Protection against tier-2 SHIV challenge by immunization with ALVAC-HIV prime and ALVAC + pentavalent gp120 protein boost in rhesus macaques	2015 CAVD Annual Meeting	Todd Bradley	Montefiori: Ab VIMC
Development and Implementation of an International Proficiency Testing Program for the Neutralizing Antibody Assay for HIV-1 in TZM-bl Cells	Society for Quality Assurance Annual Meeting –Apr 2010 - Cincinnati, OH	Todd, C A	Self: VISC
Development and Implementation of an International Proficiency Testing Program for a Neutralizing Antibody Assay for HIV-1 in TZM-bl Cells	AIDS Vaccine 2009, Paris	Todd, CA	Self: VISC
Software Validation In A GCLP Academic Environment	Society for Quality Assurance Annual Meeting	Todd, Christopher
Specificities of Elite Broadly Neutralizing Sera from HIV-1-Infected Individuals	AIDS Vaccine 2010, Atlanta	Tomaras, G.D.
Enzyme Digests Eliminate Non-Functional Env from HIV-1 Particle Surfaces Leaving Native Env Trimers Intact and Viral Infectivity Unaffected	AIDS Vaccine, 2011, Bangkok Thailand	Tong, T.
Purification of Native Env Trimers in Particulate and Soluble Forms and an Analysis of Their Stability and Antigenicity	AIDS Vaccine, 2011, Bangkok Thailand	Tong, T.
Structure-based stabilization of soluble cleaved HIV-1 envelope glycoprotein trimers	Keystone HIV Vaccines	Torrents de la Peña A
Clinical Development of a Novel CD1d-Binding NKT Cell Ligand as an Adjuvant	International Symposium on CD1 and NKT Cells 2011 - Chicago	Tsuji, M.
Modulation of the complex pathways as a biomarker of protection against HIV and as a means to improve vaccine efficacy	Keystone, Banff	Vaccari, Monica
Safety, Tolerability and Acceptability of Electroporation to Deliver ADVAX, a Clade C/B’ DNA-Based Candidate HIV-1 Vaccine, to Healthy Volunteers	AIDS Vaccine 2008 - Cape Town	Vasan, S
In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers	AIDS Vaccine 2009 - Paris	Vasan, S	Koup: T Cell VIMC;#Parks: Replicating Viral Vaccine Vectors
DNA Vector/Electroporation Immunogenicity Trials	AIDS Vaccine 2010 - Atlanta	Vasan, S	Koup: T Cell VIMC
A Novel Glycolipid Adjuvant Significantly Boosts Cellular Immune Responses to an Adenoviral Vaccine in Non Human Primates	AIDS Vaccine 2011 - Bangkok	Vasan, S
In Vivo Electroporation Enhances the Immunogenicity of ADVAX, a DNA-based HIV-1 Vaccine Candidate, in Healthy Volunteers.	DNA Vaccines 2010 - New Orleans	Vasan, S.
Characterization of B cell superantigen activity by membrane proximal external region 2F5 epitope in HR2 peptide-immunized mice	AIDS Vaccine 2007 - Seattle	Verkoczy, L
Immunological Tolerance Prevents the Expression of a Broadly Reactive Neutralizing HIV-1 Antibody	AIDS Vaccine 2009, Paris	Verkoczy, L
Dissection of the contributions of Immunoglobulin light chains and MPER specificity in counterselection of B cells expressing the Broadly Neutralizing antibody 2F5	AIDS Vaccine 2010, Atlanta	Verkoczy, Laurent
Development of an Ad5 ELISA: Beyond Neutralizing Antibodies	AIDS Vaccine 2008, Cape Town	Vogt, J
Construction of a Yellow Fever Virus Vector and Characterization Utilizing SIV Gene Inserts	AIDS Vaccine 2010, Atlanta	Vogt, Jennifer
Global HIV Vaccine Research Cryorepository - GHRC	AIDS Vaccine 2008, Cape Town	von Briesen, H
Sample quality and integrity: Is standardization an achievable goal or a dream? MODERN BIOBANKING TECHNOLOGIES TO ADVANCED BIOMEDICAL RESEARCH AND DEVELOPMENT	Global Biobanking Summit, 02.-03.10.2012, London	von Briesen, Hagen
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection	Keystone Symposium, HIV Vaccines (X8)	Wagh, K.	Barouch: Therapeutic Efficacy of Potent Broadly Neutralizing mAbs for HIV-1 Eradication;#Nussenzweig: Discovery & Characterization of bNAbs;#Koff: IAVI Neutralizing Antibody Consortium
Optimal Combinations of Broadly Neutralizing Monoclonal Antibodies for the Prevention and Therapeutic Treatment of HIV-1 Clade C Infections	CAVD Annual Meeting – Norm Letvin Early Career Investigator Symposium	Wagh, K.
Antibodies for Prevention of Subtype A, C & D HIV-1 Infection	HIVR4P, Chicago, IL	Wagh, K.	Barouch, Bill and Melinda Gates Foundation, Hassell, Ho, Nussenzweig
Engineering and characterization of soluble heterotrimeric gp140-Envelope glycoproteins from HIV	AIDS Vaccine 2007 - Seattle	Wallace, A
rAd prime/rLCMV boost regimen induces long-lasting HIV-1-spcific humoral and cellular immune responses in mice.	Keystone 2010	Wang, L
Allogeneic stimulation of the innate anti-viral factor APOBEC3G expression in human memory CD4+ T cells and prevention of SHIV infectivity in macaques immunized with recombinant HLA antigens	AIDS Vaccine 2009, Paris	Wang, Y
Control of HIV Viral Replication Mediated by the Synergistic Effects of Unique Combinations of HLA Class I Alleles	Keystone, 2011, Whistler, British Columbia, Canada	Wang, Yaoyu, E
HIV-1 Infection mediated by cell-cell interaction is resistant to neutralizing antibody	AIDS Vaccine 2010, Atlanta	Wei, Q.
Llama antibody fragments with broad HIV-1 crossneutralizing activity	AIDS Vaccine 2007 - Seattle	Weiss, RA
Few and far between: How HIV may be evading antibody avidity and what we can do about it?	AIDS Vaccine 2010, Atlanta	West, Jr., Anthony P.
Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120	AIDS Vaccine 2012, Boston, MA	West, Jr., Anthony, P.
Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues	Keystone Symposia - HIV Vaccines, Keystone, Colorado	West, Jr., Anthony, P.	Nussenzweig: Discovery & Characterization of bNAbs
HIV-1 neutralization is impacted by the PBMC donor used for both virus growth and target cells, and the effects are neutralization reagent-specific	AIDS Vaccine 2009, Paris	Wieczorek, L
Simulation of an MPER Peptide Samples Epitope Conformations of Two Broadly Neutralizing Antibodies	AIDS Vaccine 2009, Paris	Wiehe, K
Broad Neutralization by Multiple MPER-directed Antibodies Isolated from Chronically HIV-1-infected African Donors with Evidence of 10E8-like Plasma Neutralization Breadth	National CFAR Conference - November 2015	Williams, LaTonya D	Montefiori: Ab VIMC
The Memory B Cell and Serum Antibody Repertoire Share Clonal Lineage Members of HIV-1 gp41 Broadly Neutralizing Antibodies	Keystone 2016	Williams, LaTonya D	Montefiori: Ab VIMC
IgG3 Subclass and Specificity Profiles Elicited by the RV305 Vaccine Regimen	Keystone 2015	Williams, LaTonya D	Montefiori: Ab VIMC
Development of Outer Domain Env Immunogens to Elicit Broadly Neutralizing Antibodies	AIDS Vaccine 2008, Cape Town	Wu, L
Guiding the immune system through complex maturation pathways – a novel multi-immunogen approach for elicitation of known broadly neutralizing antibodies	AIDS Vaccine 2009, Paris	Xiao, X
Production, Biophysical Characterization and Structure Determination of Computationally Derived HIV gp140 Epitope-Scaffolds	11th Annual Joint Research Sympoisum 2007 - Seattle	Xu, C
Putative Lipid-phosphate Head Group Binding Site on the Broadly Neutralizing Anti-HIV Antibody 4E10	Keystone 2009	Xu, H
The Specific Phospholipid Binding and Neutralizing Activities of the Anti-HIV Antibody 4E10 are Separable	AIDS Vaccine 2009, Paris	Xu, H	Reinherz: bNAbs Against Clade C
Antigenicity And Immunogenicity Of A VRC01 Germline-Binding Immunogen	IDPT	Xuejun Chen
Characterization of CD4 Independent HIV-1 Envelope as Potential Immunogens	CROI, Seattle WA	Yang, Lifei
Vaccine-Elicited IgG Subclasses and Functional Antibodies	AIDS Vaccine 2010, Atlanta	Yates, Nicole, L.	Zolla-Pazner: Epitope-Scaffold Immunogens
Differential Regulation of HIV-Specific IgG Subclass Antibodies Following Infection Versus Vaccination	HIV Acute Infection Meeting - Boston	Yates, NL	Haynes: Broad Neutralizing Antibody Consortium;#McElrath: Innate to Adaptive Immunity;#Montefiori: Ab VIMC
Application of systems biology to identify predictors of HIV Vaccine Immunogenicity	AIDS Vaccine 2008, Cape Town	Zak, D
Systems analysis of HIV/SIV vaccine immunogenicity	Keystone Symposia - Immunological Mechanisms of Vaccination, 2010, Seattle	Zak, Dan
Systems Analysis of HIV Vaccine Triggered Innate Immune Responses	AIDS Vaccine 2012, Boston	Zak, Daniel
Cross-Reactive HIV-Neutralizing Human Monoclonal Antibody which Recognizes Novel Conformational Epitope on gp41, Lacks Reactivity against Self Antigens	AIDS Vaccine 2007 - Seattle	Zhang, M
A recombinant canine distemper virus vector expressing SIV Gag replicates in ferret gut-associated lymphoid tissues and is immunogenic.	AIDS Vaccine 2010, Atlanta	Zhang, Xinsheng
Genotypic and phenotypic characteristics of CRF01_AE HIV‐1 virus env genes from early infected individuals	AIDS Vaccine 2010, Atlanta	Zhao, C.
New broadly neutralizing human monoclonal antibodies targeting the 2F5 epitope	AIDS Vaccine 2010, Atlanta	Zhu, Z	Montefiori: Ab VIMC
Software Tools for Profiling Intra-host Viral Diversity from Ultra-Deep Sequence	Advances in Genome Biology and Technology, 2011, Maro Island, FL	Zody, Michael
Induction of Cross-clade, Anti-V3 Neutralizing Antibodies in Rabbits Using a DNA Prime/Protein Boost Immunization Regimen	AIDS Vaccine 2008, Cape Town	Zolla-Pazner, S
Focusing the Immune Response on the V3 Loop of the HIV-1 gp120 Envelope Induces Cross-Clade Neutralizing Antibodies	AIDS Vaccine 2007 - Seattle	Zolla-Pazner, S
Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes	AIDS Vaccine 2009, Paris	Zolla-Pazner, S	Self: VISC
Induction of Cross-clade Neutralizing Antibodies with a Prime/Boost Vaccine Strategy Focused on a Neutralizing Epitope	AIDS Vaccine 2009, Paris	Zolla-Pazner, S
A V2 Conformational Immunodominant Epitope Recognized by Human Monoclonal Antibodies	AIDS Vaccine - Barcelona, Spain	Zolla-Pazner, S.	Nussenzweig: Discovery & Characterization of bNAbs;#Montefiori: Ab VIMC
Neutralizing Antibody Responses Induced with V3-Scaffold Protein Boots Following Priming with gp120 DNA	AIDS Vaccine - Bangkok, Thailand	Zolla-Pazner, S.	Lu: Creating a Better Envelope;#Montefiori: Ab VIMC
Using Epitopes Recognized by Monoclonal Antibodies as Vaccine Templates	Institute of Human Virology 12th Annual International Meeting, Italy, 2010	Zolla-Pazner, Susan
Identifying mycobacterial factors modulating autophagy.	Southeastern Tuberculosis meeting, 2010, Durham, NC	Zullo, AJ	Haynes: Broad Neutralizing Antibody Consortium

javascript: SP.SOD.executeFunc('followingcommon.js', 'FollowDoc', function() { FollowDoc('{ListId}', {ItemId}); });

0x0

ContentType

0x01

1100

Run now

/_layouts/images/HarePointScheduler/run_now.png

javascript: void(HarePointScheduler.ContextClick('Run_now', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x0037D1A977040C4133BE7822D7AF2D22DD

Enable

/_layouts/images/HarePointScheduler/enable.png

javascript: void(HarePointScheduler.ContextClick('Enable', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x0037D1A977040C4133BE7822D7AF2D22DD00A36433F5D1584B3D8625A0D95311AB7C

Disable

/_layouts/images/HarePointScheduler/disable.png

javascript: void(HarePointScheduler.ContextClick('Disable', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x0037D1A977040C4133BE7822D7AF2D22DD0030C14E73870D4F3D8F23EF41728D8A67

Stop Instances

/_layouts/images/HarePointScheduler/stop.png

javascript: void(HarePointScheduler.ContextClick('Stop_instances', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x0037D1A977040C4133BE7822D7AF2D22DD

Stop Instance

/_layouts/images/HarePointScheduler/stop.png

javascript: void(HarePointScheduler.ContextClick('Stop_instance', '{ListId}', '{ItemId}'));

0x0

0x4

ContentType

0x002CBCC5F171F54C4B8FB601813349C162

Compliance Details

javascript:if(CalloutManager && CalloutManager.closeAll) CalloutManager.closeAll(); commonShowModalDialog('{SiteUrl}'+ '/_layouts/15/itemexpiration.aspx' +'?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/hold.aspx' +'?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/Reporting.aspx' +'?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+ '/_layouts/15/expirationconfig.aspx' +'?ID={ItemId}&List={ListId}'); return false;}}, null);

0x0

0x1

ContentType

0x01

898

Document Set Version History

/_layouts/15/images/versions.gif?rev=40

javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}'+ '/_layouts/15/DocSetVersions.aspx' + '?List={ListId}&ID={ItemId}')

0x0

ContentType

0x0120D520

330

Send To other location

/_layouts/15/images/sendOtherLoc.gif?rev=40

javascript:GoToPage('{SiteUrl}' + '/_layouts/15/docsetsend.aspx' + '?List={ListId}&ID={ItemId}')

0x0

ContentType

0x0120D520

350